File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Altered expression levels of microRNA-132 and Nurr1 in peripheral blood of Parkinson's disease: potential disease biomarkers

TitleAltered expression levels of microRNA-132 and Nurr1 in peripheral blood of Parkinson's disease: potential disease biomarkers
Authors
KeywordsParkinson’s disease
miR-132
Nurr1
biomarker
peripheral blood
Issue Date2019
PublisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/page/acncdm/about.html
Citation
ACS Chemical Neuroscience, 2019, v. 10 n. 5, p. 2243-2249 How to Cite?
AbstractMicroRNAs (miRNAs) are small and evolutionary conserved noncoding RNAs that are involved in post-transcriptional gene regulation. Differential expression levels of miRNAs can be used as potential biomarkers of disease. Previous animal studies have indicated that the expression level of miR-132 is negatively correlated with its downstream molecule nuclear receptor related 1 protein (Nurr1), which is one of the key factors for the maintenance of dopaminergic function and is particularly vulnerable in Parkinson’s disease (PD). However, this correlation has not been confirmed in human patients with PD. Moreover, the possible involvement of miR-132 during the pathogenesis and progression of PD is not fully investigated. Therefore, in the present study, we determined the peripheral circulation levels of miR-132 and Nurr1 in patients with PD, neurological disease controls (NDC) and healthy controls (HC) by reverse transcription real-time quantitative PCR (RT-qPCR). Our data clearly demonstrated that the plasma miR-132 level in PD was significantly higher than those in HC (178%, p < 0.05) and NDC (188%, p < 0.001). When adjusted for gender and age, higher level of miR-132 expression was associated with the significantly increased risk for PD in males and was closely related with the disease stages and disease severity. Furthermore, peripheral Nurr1 was significantly decreased in PD compared with HC (56%, p < 0.001) and NDC (58%, p < 0.001). Much more interestingly, further analysis revealed a negative correlation between the decreased Nurr1 level and the elevated miR-132 level in PD. All these findings indicated that the combination of a high miR-132 level with the low level of its downstream Nurr1 might be a potential biomarker aiding in the diagnosis of PD and monitoring disease progression.
Persistent Identifierhttp://hdl.handle.net/10722/276231
ISSN
2017 Impact Factor: 4.211
2015 SCImago Journal Rankings: 1.842

 

DC FieldValueLanguage
dc.contributor.authorYang, Z-
dc.contributor.authorYan, T-
dc.contributor.authorLi, S-
dc.contributor.authorWei, M-
dc.contributor.authorQi, H-
dc.contributor.authorShen, B-
dc.contributor.authorChang, RCC-
dc.contributor.authorLe, W-
dc.contributor.authorPiao, F-
dc.date.accessioned2019-09-10T02:58:39Z-
dc.date.available2019-09-10T02:58:39Z-
dc.date.issued2019-
dc.identifier.citationACS Chemical Neuroscience, 2019, v. 10 n. 5, p. 2243-2249-
dc.identifier.issn1948-7193-
dc.identifier.urihttp://hdl.handle.net/10722/276231-
dc.description.abstractMicroRNAs (miRNAs) are small and evolutionary conserved noncoding RNAs that are involved in post-transcriptional gene regulation. Differential expression levels of miRNAs can be used as potential biomarkers of disease. Previous animal studies have indicated that the expression level of miR-132 is negatively correlated with its downstream molecule nuclear receptor related 1 protein (Nurr1), which is one of the key factors for the maintenance of dopaminergic function and is particularly vulnerable in Parkinson’s disease (PD). However, this correlation has not been confirmed in human patients with PD. Moreover, the possible involvement of miR-132 during the pathogenesis and progression of PD is not fully investigated. Therefore, in the present study, we determined the peripheral circulation levels of miR-132 and Nurr1 in patients with PD, neurological disease controls (NDC) and healthy controls (HC) by reverse transcription real-time quantitative PCR (RT-qPCR). Our data clearly demonstrated that the plasma miR-132 level in PD was significantly higher than those in HC (178%, p < 0.05) and NDC (188%, p < 0.001). When adjusted for gender and age, higher level of miR-132 expression was associated with the significantly increased risk for PD in males and was closely related with the disease stages and disease severity. Furthermore, peripheral Nurr1 was significantly decreased in PD compared with HC (56%, p < 0.001) and NDC (58%, p < 0.001). Much more interestingly, further analysis revealed a negative correlation between the decreased Nurr1 level and the elevated miR-132 level in PD. All these findings indicated that the combination of a high miR-132 level with the low level of its downstream Nurr1 might be a potential biomarker aiding in the diagnosis of PD and monitoring disease progression.-
dc.languageeng-
dc.publisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/page/acncdm/about.html-
dc.relation.ispartofACS Chemical Neuroscience-
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in [JournalTitle], copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles on Request author-directed link to Published Work, see http://pubs.acs.org/page/policy/articlesonrequest/index.html].-
dc.subjectParkinson’s disease-
dc.subjectmiR-132-
dc.subjectNurr1-
dc.subjectbiomarker-
dc.subjectperipheral blood-
dc.titleAltered expression levels of microRNA-132 and Nurr1 in peripheral blood of Parkinson's disease: potential disease biomarkers-
dc.typeArticle-
dc.identifier.emailChang, RCC: rccchang@hku.hk-
dc.identifier.authorityChang, RCC=rp00470-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1021/acschemneuro.8b00460-
dc.identifier.pmid31317606-
dc.identifier.scopuseid_2-s2.0-85069865035-
dc.identifier.hkuros303913-
dc.identifier.volume10-
dc.identifier.issue5-
dc.identifier.spage2243-
dc.identifier.epage2249-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats